Basic Information


GTO ID GTC3575
Trial ID NCT06019702
Disease Gastrointestinal System Cancer
TherapymRNA vaccine
Treatment iNeo-Vac-R01
PhasePhase1
Recruitment statusRecruiting
TitleA Clinical Study to Assess the Safety, Feasibility, and Efficacy of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
Year2023
CountryChina
Company sponsorSir Run Run Shaw Hospital
Other ID(s)SRRSH2023-755-01

Clinical Result

Cohort1: iNeo-Vac-R01_dose level 1
Administration route hypodermic injection
Dosage iNeo-Vac-R01, 50 μg, Day 1 of each 21-day cycle for up to 9 cycles
Age Adult, Older_Adult
Cohort2: iNeo-Vac-R01_dose level 2
Administration route hypodermic injection
Dosage iNeo-Vac-R01, 100 μg, Day 1 of each 21-day cycle for up to 9 cycles
Age Adult, Older_Adult
Cohort3: iNeo-Vac-R01_dose level 3
Administration route hypodermic injection
Dosage iNeo-Vac-R01, 150 μg, Day 1 of each 21-day cycle for up to 9 cycles
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph